El resultado debe valorarse teniendo en cuenta la masa muscular, el entrenamiento reciente, la dieta y otros indicadores
Competitive Positioning 11.2 Market Share Analysis of Glucagon-Like Peptide 1 (GLP-1) Agonist Market 11.3 Company Profiles 11.3.1 Eli Lilly and Company 11.3.2 Pfizer 11.3.3 Sanofi 11.3.4 AstraZeneca PLC 11.3.5 Boehringer Ingelheim 11.3.6 Novo Nordisk List of Figures Figure 2: People with diabetes in Thousands, (20-79 y) Figure 3: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020-2022 (USD Million) Figure 4: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2023-2030 (USD Million) Figure 5: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market CAGR (%), By Value, 2020-2023, 2024-2030 Figure 6: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR) Figure 7: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Tirzepatide, 2020-2030 (USD Million) Figure 8: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR) Figure 9: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Semaglutide, 2020-2030 (USD Million) Figure 10: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR) Figure 11: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Dulaglutide, 2020-2030 (USD Million) Figure 12: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR) Figure 13: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Other Types, 2020-2030 (USD Million) Figure 14: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) Figure 15: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Clinics, 2020-2030 (USD Million) Figure 16: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) Figure 17: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Ambulatory Surgical Centers, 2020-2030 (USD Million) Figure 18: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) Figure 19: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Hospitals, 2020-2030 (USD Million) Figure 20: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR) Figure 21: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Oral, 2020-2030 (USD Million) Figure 22: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) Figure 23: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million) Figure 24: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) Figure 25: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Type 2 Diabetes, 2020-2030 (USD Million) Figure 26: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR) Figure 27: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By NASH, 2020-2030 (USD Million) Figure 28: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) Figure 29: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Obesity, 2020-2030 (USD Million) Figure 30: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million) Figure 31: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 32: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) Figure 33: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) Figure 34: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) Figure 35: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR) Figure 36: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) Figure 37: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) Figure 38: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR) Figure 39: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) Figure 40: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 41: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 42: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 43: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 44: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 45: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 46: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 47: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 48: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 49: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 50: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 51: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 52: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 53: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 54: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 55: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million) Figure 56: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 57: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) Figure 58: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) Figure 59: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) Figure 60: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR) Figure 61: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) Figure 62: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) Figure 63: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR) Figure 64: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) Figure 65: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 66: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 67: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 68: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 69: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 70: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 71: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 72: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 73: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 74: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 75: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 76: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 77: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 78: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 79: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 80: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 81: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 82: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 83: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 84: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 85: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 86: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 87: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 88: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 89: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 90: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million) Figure 91: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 92: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) Figure 93: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) Figure 94: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) Figure 95: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR) Figure 96: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) Figure 97: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) Figure 98: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR) Figure 99: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) Figure 100: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 101: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 102: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 103: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%) Figure 104: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 105: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 106: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 107: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 108: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%) Figure 109: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%) Figure 110: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 111: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 112: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 113: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%) Figure 114: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%) Figure 115: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 116: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 117: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 118: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%) Figure 119: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%) Figure 120: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR) Figure 121: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million) Figure 122: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%) Figure 123: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%) Figure 124: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%) Figure 125: Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million) Figure 126: Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%) Figure 127: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) Figure 128: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) Figure 129: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) Figure 130: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR) Figure 131: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) Figure 132: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) Figure 133: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR) Figure 134: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) Figure 135: Market Share of Prominent Companies of Glucagon-Like Peptide 1 (GLP-1) Agonist Market, 2022 (%) Figure 136: Eli Lilly and Company Revenues, 2020-2022 (USD Million) Figure 137: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%) Figure 138: Eli Lilly and Company Revenue , By Therapeutic Area, 2022 (%) Figure 139: Pfizer Revenues, 2020-2022 (USD Million) Figure 140: Pfizer Revenues, By Business Segments, 2022 (%) Figure 141: Pfizer Inc
Elevated hsCRP correlates with disease activity, cardiovascular risk, and kidney involvement
BioID Identification of Lamin-Associated Proteins
Authentic Product India's Leading Generic Pharmacy Secure Payment By LA RENON HEALTHCARE PRIVATE LIMITED MRP 1287.58 1094.44 15 % OFF 109.44 Only / Tablet -- Composition Content Reviewed By: Dr
She was treated by multiple providers and ultimately placed on a combination of beta-blocker (metoprolol), funny current inhibitor (ivabradine), and an alpha-1-agonist (midodrine)
